(Q28681550)

English

Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons

scientific article (publication date: 13 August 2013)

In more languages

Statements

scholarly article

0 references

Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons (English)

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

Peter Vickerman

object named as

Peter Vickerman

6

0 references

Matthew Hickman

object named as

Matthew Hickman

2

0 references

Sharon J Hutchinson

4

object named as

Sharon J Hutchinson

0 references

author name string

Natasha K Martin

1

0 references

Alec Miners

3

0 references

Avril Taylor

5

0 references

language of work or name

0 references

publication date

13 August 2013

0 references

0 references

3

0 references

8

0 references

e003153

0 references

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

17 March 2017

Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

17 March 2017

Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

17 March 2017

The changing therapeutic landscape for hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Limited uptake of hepatitis C treatment among injection drug users

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Modelling the hepatitis B vaccination programme in prisons.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Screening for Hepatitis C in injecting drug users: a cost utility analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Managing chronic hepatitis C acquired through intravenous drug use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Management of chronic hepatitis C: clinical audit of biopsy based management algorithm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

3 June 2018

Low incidence of hepatitis C virus among prisoners in Scotland

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Economic model of a birth cohort screening program for hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Case finding for hepatitis C in primary care: a cost utility analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3752052

27 November 2018

Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anonymous HIV surveillance with risk factor elicitation at Scotlandʼs largest prison, Barlinnie

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/23943776

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJOPEN-2013-003153

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28681550&oldid=1785392291"